Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

E. Lengfelder, F. Lo-Coco, L. Ades, P. Montesinos, D. Grimwade, B. Kishore, S. M. Ramadan, M. Pagoni, M. Breccia, A. J G Huerta, A. M. Nloga, J. D. González-Sanmiguel, A. Schmidt, J. F. Lambert, S. Lehmann, E. Di Bona, B. Cassinat, W. K. Hofmann, D. Görlich, M. C. SauerlandP. Fenaux, M. Sanz

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74% in hematological and 62% in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-up, the 3-year overall survival (OS) and cumulative incidence of second relapse were 68% and 41% in hematological relapse, 66% and 48% in molecular relapse and 90 and 11% in extramedullary relapse, respectively. After allogeneic or autologous transplantation in second CR (n=93), the 3-year OS was 80% compared with 59% without transplantation (n=55) (P=0.03). Multivariable analysis demonstrated the favorable prognostic impact of first remission duration ≥1.5 years, achievement of mCR and allogeneic or autologous transplantation on OS of patients alive after induction (P=0.03, P=0.01, P=0.01) and on leukemia-free survival (P=0.006, P

Original languageEnglish
Pages (from-to)1084-1091
Number of pages8
JournalLeukemia
Volume29
Issue number5
DOIs
Publication statusPublished - May 11 2015

Fingerprint

Acute Promyelocytic Leukemia
Registries
Recurrence
Therapeutics
Survival
Autologous Transplantation
Homologous Transplantation
arsenic trioxide
Leukocytosis
Leukemia
Transplantation
Incidence

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine
  • Medicine(all)

Cite this

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia : registry results from the European LeukemiaNet. / Lengfelder, E.; Lo-Coco, F.; Ades, L.; Montesinos, P.; Grimwade, D.; Kishore, B.; Ramadan, S. M.; Pagoni, M.; Breccia, M.; Huerta, A. J G; Nloga, A. M.; González-Sanmiguel, J. D.; Schmidt, A.; Lambert, J. F.; Lehmann, S.; Di Bona, E.; Cassinat, B.; Hofmann, W. K.; Görlich, D.; Sauerland, M. C.; Fenaux, P.; Sanz, M.

In: Leukemia, Vol. 29, No. 5, 11.05.2015, p. 1084-1091.

Research output: Contribution to journalArticle

Lengfelder, E, Lo-Coco, F, Ades, L, Montesinos, P, Grimwade, D, Kishore, B, Ramadan, SM, Pagoni, M, Breccia, M, Huerta, AJG, Nloga, AM, González-Sanmiguel, JD, Schmidt, A, Lambert, JF, Lehmann, S, Di Bona, E, Cassinat, B, Hofmann, WK, Görlich, D, Sauerland, MC, Fenaux, P & Sanz, M 2015, 'Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet', Leukemia, vol. 29, no. 5, pp. 1084-1091. https://doi.org/10.1038/leu.2015.12
Lengfelder, E. ; Lo-Coco, F. ; Ades, L. ; Montesinos, P. ; Grimwade, D. ; Kishore, B. ; Ramadan, S. M. ; Pagoni, M. ; Breccia, M. ; Huerta, A. J G ; Nloga, A. M. ; González-Sanmiguel, J. D. ; Schmidt, A. ; Lambert, J. F. ; Lehmann, S. ; Di Bona, E. ; Cassinat, B. ; Hofmann, W. K. ; Görlich, D. ; Sauerland, M. C. ; Fenaux, P. ; Sanz, M. / Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia : registry results from the European LeukemiaNet. In: Leukemia. 2015 ; Vol. 29, No. 5. pp. 1084-1091.
@article{6e53a79ffe3941ac89c4c190aa1ee233,
title = "Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet",
abstract = "In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91{\%} of the patients entered complete hematological remission (CR), 7{\%} had induction death and 2{\%} resistance, 27{\%} developed differentiation syndrome and 39{\%} leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74{\%} in hematological and 62{\%} in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-up, the 3-year overall survival (OS) and cumulative incidence of second relapse were 68{\%} and 41{\%} in hematological relapse, 66{\%} and 48{\%} in molecular relapse and 90 and 11{\%} in extramedullary relapse, respectively. After allogeneic or autologous transplantation in second CR (n=93), the 3-year OS was 80{\%} compared with 59{\%} without transplantation (n=55) (P=0.03). Multivariable analysis demonstrated the favorable prognostic impact of first remission duration ≥1.5 years, achievement of mCR and allogeneic or autologous transplantation on OS of patients alive after induction (P=0.03, P=0.01, P=0.01) and on leukemia-free survival (P=0.006, P",
author = "E. Lengfelder and F. Lo-Coco and L. Ades and P. Montesinos and D. Grimwade and B. Kishore and Ramadan, {S. M.} and M. Pagoni and M. Breccia and Huerta, {A. J G} and Nloga, {A. M.} and Gonz{\'a}lez-Sanmiguel, {J. D.} and A. Schmidt and Lambert, {J. F.} and S. Lehmann and {Di Bona}, E. and B. Cassinat and Hofmann, {W. K.} and D. G{\"o}rlich and Sauerland, {M. C.} and P. Fenaux and M. Sanz",
year = "2015",
month = "5",
day = "11",
doi = "10.1038/leu.2015.12",
language = "English",
volume = "29",
pages = "1084--1091",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia

T2 - registry results from the European LeukemiaNet

AU - Lengfelder, E.

AU - Lo-Coco, F.

AU - Ades, L.

AU - Montesinos, P.

AU - Grimwade, D.

AU - Kishore, B.

AU - Ramadan, S. M.

AU - Pagoni, M.

AU - Breccia, M.

AU - Huerta, A. J G

AU - Nloga, A. M.

AU - González-Sanmiguel, J. D.

AU - Schmidt, A.

AU - Lambert, J. F.

AU - Lehmann, S.

AU - Di Bona, E.

AU - Cassinat, B.

AU - Hofmann, W. K.

AU - Görlich, D.

AU - Sauerland, M. C.

AU - Fenaux, P.

AU - Sanz, M.

PY - 2015/5/11

Y1 - 2015/5/11

N2 - In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74% in hematological and 62% in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-up, the 3-year overall survival (OS) and cumulative incidence of second relapse were 68% and 41% in hematological relapse, 66% and 48% in molecular relapse and 90 and 11% in extramedullary relapse, respectively. After allogeneic or autologous transplantation in second CR (n=93), the 3-year OS was 80% compared with 59% without transplantation (n=55) (P=0.03). Multivariable analysis demonstrated the favorable prognostic impact of first remission duration ≥1.5 years, achievement of mCR and allogeneic or autologous transplantation on OS of patients alive after induction (P=0.03, P=0.01, P=0.01) and on leukemia-free survival (P=0.006, P

AB - In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74% in hematological and 62% in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-up, the 3-year overall survival (OS) and cumulative incidence of second relapse were 68% and 41% in hematological relapse, 66% and 48% in molecular relapse and 90 and 11% in extramedullary relapse, respectively. After allogeneic or autologous transplantation in second CR (n=93), the 3-year OS was 80% compared with 59% without transplantation (n=55) (P=0.03). Multivariable analysis demonstrated the favorable prognostic impact of first remission duration ≥1.5 years, achievement of mCR and allogeneic or autologous transplantation on OS of patients alive after induction (P=0.03, P=0.01, P=0.01) and on leukemia-free survival (P=0.006, P

UR - http://www.scopus.com/inward/record.url?scp=84929280983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929280983&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.12

DO - 10.1038/leu.2015.12

M3 - Article

C2 - 25627637

AN - SCOPUS:84929280983

VL - 29

SP - 1084

EP - 1091

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -